Skip to main content

Advertisement

Table 3 Pre-treatment demographics, oncological data, and motor status of patients with central metastasis, based on the treatment modalities, namely, MRS or SRS/SRT

From: Early motor function after local treatment of brain metastases in the motor cortex region with stereotactic radiotherapy/radiosurgery or microsurgical resection: a retrospective study of two consecutive cohorts

  Overall MRS SRT/SRS p
Treatments 68 27 41  
Patients (n) 64 27 37  
Females (%) 52% 52% 52% n.s.
Age (years) 59.5 60 59 n.s.
RPA 1.83 1.85 1.81 n.s
KPI pre-operative * 78 80 78 n.s
Tumor-Volume (cm3) * 7.2 10.5 4.9 <0.02
Patients with Hemiparesis 36 24 12 <0.005
Muscle strength (BMRC)*:     
Arm 4.3 3.7 4.7 <0.008
Leg 4.6 4.3 4.8 <0.0005
NSCLC 43% 44.4% 42.4% n.s
Mamma-Ca 14.5% 18.5% 11.9% n.s.
Melanoma 13% 18.5% 9.5% n.s.
Renal Cell Ca 5.8% 0% 9.5% n.s.
CUP 5.8% 0% 9.5% n.s.
SCLC 4.3% 0% 7.1% n.s
Germ Cell Ca 4.3% 7.4% 2.4% n.s.
Gastrointestinal Ca 4.3% 3.7% 4.8% n.s.
Urothelial Cell Ca 2.9% 3.7% 2.4% n.s.
Sarcoma 1.4% 3.7% 0% n.s.
  1. SRT/SRS Stereotactic radiotherapy or radiosurgery, MRS Microsurgery, KPI Karnofsky performance index, RPA Recursive partitioning analysis, BMRC British Medical Research Council, NSCLC Non-small cell lung cancer, SCLC small cell lung cancer, Ca Carcinoma, CUP: Carcinoma of unknown primary, n.s not significant
  2. * mean value